Moody's Places Hospira's (HSP) Ratings on Review for Upgrade (PFE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AstraZeneca (AZN) Falls on Pfizer/Hospira Deal
February 5, 2015 7:33 AM ESTAstraZeneca plc (NYSE: AZN) declined Thursday after Pfizer (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) announced that they have entered into a definitive merger agreement. The stock is indicated lower by over 2% pre-market.
... MorePfizer (PFE) to Acquire Hospira (HSP) in $17B Deal
February 5, 2015 7:02 AM ESTPfizer (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the worlds leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing, accretive by $0.10 - $0.12 per share for the first full year following the close of the... More
